Abbott Labs (ABT) Shareholder Summit Securities Group LLC Increased Its Stake by $18.37 Million

April 16, 2018 - By Mary Kidd

Abbott Laboratories (NYSE:ABT) Corporate LogoDuring Q4 2017 the big money sentiment increased to 0.91. That’s change of 0.04, from 2017Q3’s 0.87. 52 investors sold all, 558 reduced holdings as ABT ratio is positive. 430 increased holdings while 123 funds bought holdings. Funds hold 1.22 billion shares thus 0.64% more from 2017Q3’s 1.21 billion shares. Miracle Mile Limited Liability Co invested in 0.05% or 5,400 shs. Livforsakringsbolaget Skandia Omsesidigt reported 43,617 shs. Harvey Investment Co Ltd Liability Co has invested 2.5% in Abbott Laboratories (NYSE:ABT). Eagleclaw Managment Ltd Liability Corporation holds 0.16% in Abbott Laboratories (NYSE:ABT) or 5,518 shs. Stonebridge Cap Advisors invested in 5,942 shs or 0.08% of the stock. Penobscot Incorporated owns 44,273 shs. 100,785 were reported by Meyer Handelman. Moreover, Whittier Tru Company has 0.8% invested in Abbott Laboratories (NYSE:ABT) for 400,195 shs. Chilton Investment Limited Liability Com has 0.01% invested in Abbott Laboratories (NYSE:ABT). Employees Retirement System Of Ohio accumulated 1.25 million shs. Glenview Bancorporation Trust Dept holds 1.7% in Abbott Laboratories (NYSE:ABT) or 64,785 shs. Finemark Financial Bank And Tru has 0.36% invested in Abbott Laboratories (NYSE:ABT) for 98,318 shs. Altavista Wealth Mngmt invested in 6,137 shs or 0.15% of the stock. Atria Investments Ltd Liability Co stated it has 61,950 shs. Moreover, Cohen Mngmt Inc has 0.13% invested in Abbott Laboratories (NYSE:ABT) for 10,038 shs.

ABT had 19 sales and 1 buying transaction since October 23, 2017. This’s net activity of $28.95 million. 6,284 shs valued at $375,381 were sold by Contreras Jaime on Wednesday, February 28. Watkin Jared sold $58,635 worth of stock. 11,106 Abbott Laboratories (NYSE:ABT) shs with value of $667,804 were sold by Fussell Stephen R. Blaser Brian J sold $1.73 million worth of stock. Salvadori Daniel Gesua Sive also sold $53,369 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28. Shares for $84,344 were sold by MANNING JOSEPH J on Wednesday, February 28.

Summit Securities Group Llc upped its stake by 27315.25% in Abbott Labs (ABT), according to 2017Q4 Securities and Exchange form. The company’s stock popped up 5.88% while Summit Securities Group Llc bought 322,320 shares. The major pharmaceuticals company at the end of 2017Q4 was priced at $18.46M. It’s up from 1,180 at the end of the previous reported quarter. Now it had 323,500 shares held by the institutional investor . Summit Securities Group Llc has cut its stake in and also reduced its holding in Spdr Dow Jones Indl Avrg Etf (DIA) by 18,700 shares in the quarter, for a total of 8,200 shares.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 15 analysts cover Abbott Labs (NYSE:ABT). “Buy” rating has 13, “Sell” are 0, while 2 are “Hold”. 87% are bullish. 26 are the (NYSE:ABT)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. On Thursday, January 25 Wells Fargo maintained Abbott Laboratories (NYSE:ABT) rating. Wells Fargo has “Outperform” rating and $70 target. In Wednesday, January 24 report Jefferies maintained the stock with “Buy” rating. On Thursday, January 25 the rating was maintained by JP Morgan with “Overweight”. The company rating was maintained by Citigroup on Thursday, October 19. On Tuesday, January 2 the firm has “Overweight” rating given by Morgan Stanley. On Wednesday, January 24 the firm has “Buy” rating given by BMO Capital Markets. On Thursday, January 25 the firm earned “Buy” rating by William Blair. On Thursday, January 25 the company was maintained by Morgan Stanley. On Wednesday, January 24 the rating was maintained by RBC Capital Markets with “Buy”. On Thursday, October 19 the firm earned “Buy” rating by RBC Capital Markets.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: